Boston Scientific appoints COO. Boston Scientific stock is valued at USD 66.1 billion
Published on 10/23/2026 at 10:31 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSOperations and earnings ahead
- Boston Scientific announced Joseph Fitzgerald's COO appointment on October 7, 2026, alongside three segments.
- Second-quarter revenue reached USD 5.44 billion, up 7.50 percent year over year.
- Boston Scientific stock traded at EUR 41.10 at 10:29 a.m. CEST at Lang & Schwarz on October 23, 2026.
- Third-quarter results are scheduled for October 28, 2026, before the US market opens.
Boston Scientific (ISIN US1011371077) was trading at EUR 41.10 at Lang & Schwarz on October 23, 2026 at 10:29 a.m. CEST. The company had announced on October 7 that Joseph M. Fitzgerald would become executive vice president and chief operating officer from January 1, 2027, according to Boston Scientific.
Three segments start in 2027
Fitzgerald will oversee global operations, business units and regions. The new structure will create three reportable segments from January 1, 2027: Interventional Therapies, Rhythm Solutions and MedSurg. The company said the arrangement is intended to speed decision-making and support investment allocation.
The reorganization follows a difficult earnings setup. In the second quarter of 2026, Boston Scientific generated USD 5.44 billion in revenue, an increase of 7.50 percent from the same quarter a year earlier, according to MarketBeat. The company reported adjusted earnings per share of USD 0.86 against consensus of USD 0.83, while its third-quarter adjusted earnings guidance was USD 0.80 to USD 0.82.
What does the reorganization mean for growth?
The operating split gives investors a clearer framework for tracking performance across the companys product groups. That matters because management had lowered full-year 2026 organic revenue-growth guidance to 5 percent to 6 percent, while third-quarter organic growth guidance stood at 3 percent to 5 percent.
Three dated developments
On July 29, 2026, Boston Scientific reported second-quarter revenue of USD 5.44 billion. On October 3, 2026, Sanford C. Bernstein reaffirmed an Outperform rating and set a USD 54.00 price objective, according to MarketBeat. On October 7, 2026, the company appointed Fitzgerald and announced the three-segment structure.
Upcoming dates for investors
Boston Scientific is scheduled to report third-quarter 2026 results on October 28, 2026, before the US market opens, according to comdirect. The COO appointment and the new segment structure take effect on January 1, 2027.
Stock price and valuation context
The stock was trading at EUR 41.10 at Lang & Schwarz on October 23, 2026 at 10:29 a.m. CEST. A market profile dated October 20, 2026 listed a market capitalization of USD 66.1 billion and a 52-week range of USD 41.39 to USD 105.65.
The further course of trading is shown by the continuously updated real-time quote of Boston Scientific stock.
Boston Scientific stock facts
- Company: Boston Scientific Corporation
- ISIN: US1011371077
- WKN: 884113
- Ticker: BSX
- Primary exchange: NYSE
- Price Lang & Schwarz (as of October 23, 2026, 10:29 a.m. CEST): EUR 41.10
- Market capitalization: USD 66.1 billion (as of October 20, 2026)
- 52-week range: USD 41.39-105.65 (as of October 20, 2026)
- Sector / Industry: Healthcare / Medical devices
- Next earnings date: October 28, 2026
Market context: Market report S&P 500.
